Surface Oncology Competitors

Surface Oncology (NASDAQ:SURF) and Immunovant (NASDAQ:IMVT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, earnings, profitability and institutional ownership.

Profitability

This table compares Surface Oncology and Immunovant's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings for Surface Oncology and Immunovant, as provided by MarketBeat.com.

Surface Oncology currently has a consensus target price of $12.00, suggesting a potential upside of 33.04%. Immunovant has a consensus target price of $44.4375, suggesting a potential upside of 199.24%. Given Immunovant's stronger consensus rating and higher probable upside, analysts clearly believe Immunovant is more favorable than Surface Oncology.

Insider & Institutional Ownership

52.0% of Surface Oncology shares are held by institutional investors. Comparatively, 40.2% of Immunovant shares are held by institutional investors. 35.0% of Surface Oncology shares are held by insiders. Comparatively, 0.2% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Surface Oncology and Immunovant's revenue, earnings per share and valuation.

Surface Oncology has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Surface Oncology, indicating that it is currently the more affordable of the two stocks.

Summary

Surface Oncology beats Immunovant on 6 of the 11 factors compared between the two stocks.

Surface Oncology (NASDAQ:SURF) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Profitability

This table compares Surface Oncology and Alector's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Surface Oncology and Alector, as reported by MarketBeat.

Surface Oncology presently has a consensus price target of $12.00, indicating a potential upside of 33.04%. Alector has a consensus price target of $33.6667, indicating a potential upside of 93.15%. Given Alector's stronger consensus rating and higher possible upside, analysts plainly believe Alector is more favorable than Surface Oncology.

Earnings & Valuation

This table compares Surface Oncology and Alector's top-line revenue, earnings per share and valuation.

Surface Oncology has higher earnings, but lower revenue than Alector. Alector is trading at a lower price-to-earnings ratio than Surface Oncology, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Surface Oncology has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500. Comparatively, Alector has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.

Institutional & Insider Ownership

52.0% of Surface Oncology shares are owned by institutional investors. Comparatively, 61.5% of Alector shares are owned by institutional investors. 35.0% of Surface Oncology shares are owned by company insiders. Comparatively, 13.9% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Alector beats Surface Oncology on 8 of the 14 factors compared between the two stocks.

Atara Biotherapeutics (NASDAQ:ATRA) and Surface Oncology (NASDAQ:SURF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Valuation and Earnings

This table compares Atara Biotherapeutics and Surface Oncology's top-line revenue, earnings per share (EPS) and valuation.

Surface Oncology has higher revenue and earnings than Atara Biotherapeutics. Surface Oncology is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Atara Biotherapeutics and Surface Oncology, as reported by MarketBeat.

Atara Biotherapeutics currently has a consensus target price of $34.25, suggesting a potential upside of 100.23%. Surface Oncology has a consensus target price of $12.00, suggesting a potential upside of 33.04%. Given Atara Biotherapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Atara Biotherapeutics is more favorable than Surface Oncology.

Profitability

This table compares Atara Biotherapeutics and Surface Oncology's net margins, return on equity and return on assets.

Institutional and Insider Ownership

52.0% of Surface Oncology shares are owned by institutional investors. 4.3% of Atara Biotherapeutics shares are owned by insiders. Comparatively, 35.0% of Surface Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Atara Biotherapeutics has a beta of 2.65, meaning that its share price is 165% more volatile than the S&P 500. Comparatively, Surface Oncology has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500.

Summary

Surface Oncology beats Atara Biotherapeutics on 7 of the 12 factors compared between the two stocks.

Vaxcyte (NASDAQ:PCVX) and Surface Oncology (NASDAQ:SURF) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Insider and Institutional Ownership

74.1% of Vaxcyte shares are held by institutional investors. Comparatively, 52.0% of Surface Oncology shares are held by institutional investors. 35.0% of Surface Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Vaxcyte and Surface Oncology's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Vaxcyte and Surface Oncology's revenue, earnings per share and valuation.

Vaxcyte has higher earnings, but lower revenue than Surface Oncology.

Analyst Recommendations

This is a summary of current recommendations and price targets for Vaxcyte and Surface Oncology, as provided by MarketBeat.com.

Vaxcyte currently has a consensus price target of $48.00, suggesting a potential upside of 85.83%. Surface Oncology has a consensus price target of $12.00, suggesting a potential upside of 33.04%. Given Vaxcyte's stronger consensus rating and higher probable upside, equities analysts clearly believe Vaxcyte is more favorable than Surface Oncology.

Summary

Vaxcyte beats Surface Oncology on 7 of the 9 factors compared between the two stocks.

Adverum Biotechnologies (NASDAQ:ADVM) and Surface Oncology (NASDAQ:SURF) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Profitability

This table compares Adverum Biotechnologies and Surface Oncology's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Adverum Biotechnologies and Surface Oncology, as reported by MarketBeat.

Adverum Biotechnologies currently has a consensus price target of $23.50, indicating a potential upside of 76.43%. Surface Oncology has a consensus price target of $12.00, indicating a potential upside of 33.04%. Given Adverum Biotechnologies' stronger consensus rating and higher possible upside, equities analysts clearly believe Adverum Biotechnologies is more favorable than Surface Oncology.

Volatility and Risk

Adverum Biotechnologies has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500. Comparatively, Surface Oncology has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500.

Insider and Institutional Ownership

97.4% of Adverum Biotechnologies shares are owned by institutional investors. Comparatively, 52.0% of Surface Oncology shares are owned by institutional investors. 12.4% of Adverum Biotechnologies shares are owned by company insiders. Comparatively, 35.0% of Surface Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Adverum Biotechnologies and Surface Oncology's gross revenue, earnings per share and valuation.

Surface Oncology has higher revenue and earnings than Adverum Biotechnologies. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than Surface Oncology, indicating that it is currently the more affordable of the two stocks.

Summary

Adverum Biotechnologies beats Surface Oncology on 7 of the 13 factors compared between the two stocks.

Coherus BioSciences (NASDAQ:CHRS) and Surface Oncology (NASDAQ:SURF) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations.

Earnings and Valuation

This table compares Coherus BioSciences and Surface Oncology's revenue, earnings per share (EPS) and valuation.

Coherus BioSciences has higher revenue and earnings than Surface Oncology. Surface Oncology is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Coherus BioSciences has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500. Comparatively, Surface Oncology has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500.

Institutional and Insider Ownership

52.0% of Surface Oncology shares are owned by institutional investors. 15.9% of Coherus BioSciences shares are owned by company insiders. Comparatively, 35.0% of Surface Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Coherus BioSciences and Surface Oncology's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations for Coherus BioSciences and Surface Oncology, as reported by MarketBeat.com.

Coherus BioSciences presently has a consensus price target of $27.8571, indicating a potential upside of 73.89%. Surface Oncology has a consensus price target of $12.00, indicating a potential upside of 33.04%. Given Coherus BioSciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Coherus BioSciences is more favorable than Surface Oncology.

Summary

Coherus BioSciences beats Surface Oncology on 10 of the 14 factors compared between the two stocks.